Identification of a novel conserved HLA-A 0201-restricted epitope from the spike protein of SARS-CoV

BMC Immunology

Volumn 10, Issue , 2009, Pages

  Lv, Yanbo ^a   Ruan, Zhihua ^a   Wang, Li ^a   Ni, Bing ^a   Wu, Yuzhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALYLLEUCYLASPARAGYLASPARTYLISOLEUCYLLEUCYLSERYLARGENYLLEUCINE; VITRONECTIN; EPITOPE; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPITOPE MAPPING; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TARGET CELL; TRANSGENIC MOUSE; VIRUS VIRULENCE; ANIMAL; CELL LINE; CORONAVIRUS; CYTOTOXICITY; GENETICS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; SECRETION;

ANIMALS; CELL LINE; CONSERVED SEQUENCE; CORONAVIRUS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN BINDING; SEVERE ACUTE RESPIRATORY SYNDROME; T-LYMPHOCYTES, CYTOTOXIC; VIRAL ENVELOPE PROTEINS;

EID: 72549102507     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-10-61     Document Type: Article

References (37)

1. Drosten C, Gunther S, Preiser W, Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003, 348:1967-76. 10.1056/NEJMoa030747, 12690091.
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348:1953-66. 10.1056/NEJMoa030781, 12690092.
3. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361:1319-25. 10.1016/S0140-6736(03)13077-2, 12711465.
4. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302:276-8. 10.1126/science.1087139, 12958366.
5. Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, Talbot PJ, Tam T, Babiuk L. Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 2005, 56:357-81. 10.1146/annurev.med.56.091103.134135, 15660517.
6. Normile D. Infectious diseases. Mounting lab accidents raise SARS fears. Science 2004, 304:659-61. 10.1126/science.304.5671.659, 15118129.
7. Orellana C. Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 2004, 4:64. 10.1016/S1473-3099(04)00911-9, 14959754.
8. Paterson R. SARS returns to China. Lancet Infect Dis 2004, 4:64. 10.1016/S1473-3099(04)00910-7, 14959753.
9. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med 2009,
10. Xu X, Gao X. Immunological responses against SARS-coronavirus infection in humans. Cell Mol Immunol 2004, 1:119-22.
11. Zhong X, Yang H, Guo ZF, Sin WY, Chen W, Xu J, Fu L, Wu J, Mak CK, Cheng CS. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J Virol 2005, 79:3401-8. 10.1128/JVI.79.6.3401-3408.2005, 1075701, 15731234.
12. Li T, Xie J, He Y, Fan H, Baril L, Qiu Z, Han Y, Xu W, Zhang W, You H. Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PLoS ONE 2006, 1:e24. 10.1371/journal.pone.0000024, 1762349, 17183651.
13. Dutta NK, Mazumdar K, Lee BH, Baek MW, Kim DJ, Na YR, Park SH, Lee HK, Kariwa H, Mai le Q. Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine. Immunol Lett 2008, 118:65-71. 10.1016/j.imlet.2008.03.003, 18440652.
14. Jin H, Xiao C, Chen Z, Kang Y, Ma Y, Zhu K, Xie Q, Tu Y, Yu Y, Wang B. Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochem Biophys Res Commun 2005, 328:979-86. 10.1016/j.bbrc.2005.01.048, 15707974.
15. See RH, Petric M, Lawrence DJ, Mok CP, Rowe T, Zitzow LA, Karunakaran KP, Voss TG, Brunham RC, Gauldie J. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J Gen Virol 2008, 89:2136-46. 10.1099/vir.0.2008/001891-0, 18753223.
16. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 2004, 101:9804-9. 10.1073/pnas.0403492101, 470755, 15210961.
17. Zakhartchouk AN, Sharon C, Satkunarajah M, Auperin T, Viswanathan S, Mutwiri G, Petric M, See RH, Brunham RC, Finlay BB. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 2007, 25:136-43. 10.1016/j.vaccine.2006.06.084, 16919855.
18. Zhi Y, Kobinger GP, Jordan H, Suchma K, Weiss SR, Shen H, Schumer G, Gao G, Boyer JL, Crystal RG. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Virology 2005, 335:34-45. 10.1016/j.virol.2005.01.050, 15823604.
19. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol 2009, 7:226-36. 10.1038/nrmicro2090, 2750777, 19198616.
20. Zhang CY, Wei JF, He SH. Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups. BMC Microbiol 2006, 6:88. 10.1186/1471-2180-6-88, 1609170, 17020602.
21. Tang X, Yin C, Zhang F, Fu Y, Chen W, Chen Y, Wang J, Jia W, Xu A. Measurement of subgroups of peripheral blood T lymphocytes in patients with severe acute respiratory syndrome and its clinical significance. Chin Med J (Engl) 2003, 116:827-30.
22. Sidney J, Grey HM, Kubo RT, Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 1996, 17:261-6. 10.1016/0167-5699(96)80542-1, 8962628.
23. Chen H, Hou J, Jiang X, Ma S, Meng M, Wang B, Zhang M, Zhang M, Tang X, Zhang F. Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. J Immunol 2005, 175:591-8.
24. Tsao YP, Lin JY, Jan JT, Leng CH, Chu CC, Yang YC, Chen SL. HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem Biophys Res Commun 2006, 344:63-71. 10.1016/j.bbrc.2006.03.152, 16630549.
25. Wang YD, Chen WF. Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein. Clin Immunol 2004, 113:151-4. 10.1016/j.clim.2004.07.004, 15451471.
26. Zhou M, Xu D, Li X, Li H, Shan M, Tang J, Wang M, Wang FS, Zhu X, Tao H. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. J Immunol 2006, 177:2138-45.
27. Huang J, Cao Y, Du J, Bu X, Ma R, Wu C. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 2007, 25:6981-91. 10.1016/j.vaccine.2007.06.047, 17709158.
28. Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002, 99:2100-6. 10.1182/blood.V99.6.2100, 11877285.
29. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. Embo J 1986, 5:943-9. 1166886, 3522223.
30. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003, 361:1773-8. 10.1016/S0140-6736(03)13413-7, 12781536.
31. Singh H, Raghava GP. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003, 19:1009-14. 10.1093/bioinformatics/btg108, 12761064.
32. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-9. 10.1007/s002510050595, 10602881.
33. Irwin MJ, Heath WR, Sherman LA. Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 1989, 170:1091-101. 10.1084/jem.170.4.1091, 2189481, 2477484.
34. Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H, Wang J. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 1998, 161:6238-44.
35. Talmor M, Mirza A, Turley S, Mellman I, Hoffman LA, Steinman RM. Generation or large numbers of immature and mature dendritic cells from rat bone marrow cultures. Eur J Immunol 1998, 28:811-7. 10.1002/(SICI)1521-4141(199803)28:03<811::AID-IMMU811>3.0.CO;2-S, 9541575.
36. Xiang R, Lode HN, Dreier T, Gillies SD, Reisfeld RA. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res 1998, 58:3918-25.
37. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, Calabresi P, Ha T, Tran TV, Tate KM. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997, 210:149-66. 10.1016/S0022-1759(97)00182-8, 9520298.